{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Blood+Coagulation%2C+Disorders&page=2", "query": { "condition": "Blood Coagulation, Disorders", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Blood+Coagulation%2C+Disorders&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-27T08:37:38.239Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06456346", "title": "Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Essential Thrombocythemia" ], "interventions": [ { "name": "Bomedemstat", "type": "DRUG" }, { "name": "Hydroxyurea", "type": "DRUG" }, { "name": "Bomedemstat placebo", "type": "DRUG" }, { "name": "Hydroxyurea placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2024-07-16", "completion_date": "2028-03-24", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-09-27T08:37:38.239Z", "location_count": 22, "location_summary": "Glendale, Arizona • Glendale, California • Palo Alto, California + 19 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Glendale", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Golden", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06456346" }, { "nct_id": "NCT00157118", "title": "Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Protein C Deficiency" ], "interventions": [ { "name": "Protein C Concentrate (Human) Vapor Heated", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baxalta now part of Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 18, "start_date": "2003-08-22", "completion_date": "2005-03-17", "has_results": false, "last_update_posted_date": "2021-05-05", "last_synced_at": "2026-09-27T08:37:38.239Z", "location_count": 12, "location_summary": "Los Angeles, California • Denver, Colorado • Atlanta, Georgia + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT00157118" }, { "nct_id": "NCT00659724", "title": "Ease of Use and Blood Clotting for the Gambro Polyflux HD-C4 Big Dialyzer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Kidney Failure" ], "interventions": [], "intervention_types": [], "sponsor": "Vantive Health LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2008-03", "completion_date": "2008-05", "has_results": true, "last_update_posted_date": "2025-07-24", "last_synced_at": "2026-09-27T08:37:38.239Z", "location_count": 2, "location_summary": "Easton, Maryland • Arlington, Virginia", "locations": [ { "city": "Easton", "state": "Maryland" }, { "city": "Arlington", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00659724" }, { "nct_id": "NCT01151423", "title": "Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acquired Thrombotic Thrombocytopenic Purpura" ], "interventions": [ { "name": "Caplacizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Ablynx, a Sanofi company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2011-01", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2023-04-04", "last_synced_at": "2026-09-27T08:37:38.239Z", "location_count": 13, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01151423" }, { "nct_id": "NCT01892969", "title": "Coagulation and Fibrinolysis in Pediatric Insulin Titration Trial (CAF-PINT)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Heart Failure", "Respiratory Failure" ], "interventions": [], "intervention_types": [], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Days", "maximum_age": "18 Years", "sex": "ALL", "summary": "14 Days to 18 Years" }, "enrollment_count": 304, "start_date": "2012-10", "completion_date": "2016-09", "has_results": false, "last_update_posted_date": "2020-07-31", "last_synced_at": "2026-09-27T08:37:38.239Z", "location_count": 25, "location_summary": "Los Angeles, California • Oakland, California • Orange, California + 19 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01892969" }, { "nct_id": "NCT01486927", "title": "An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Hemophilia A" ], "interventions": [ { "name": "rVIII-SingleChain", "type": "BIOLOGICAL" }, { "name": "Octocog alfa", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "CSL Behring", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "65 Years", "sex": "MALE", "summary": "12 Years to 65 Years · Male only" }, "enrollment_count": 175, "start_date": "2012-02", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2016-08-09", "last_synced_at": "2026-09-27T08:37:38.239Z", "location_count": 9, "location_summary": "Sacramento, California • San Diego, California • Aurora, Colorado + 6 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01486927" }, { "nct_id": "NCT00514982", "title": "Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hermanski-Pudlak Syndrome", "Colitis", "Cytokines", "Lymphocytes", "Drug Evaluation" ], "interventions": [ { "name": "Mesalamine", "type": "DRUG" }, { "name": "Infliximab", "type": "DRUG" }, { "name": "Corticosteroids", "type": "DRUG" }, { "name": "6-Mercaptopurine", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2007-08-07", "completion_date": "2011-03-08", "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-09-27T08:37:38.239Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00514982" }, { "nct_id": "NCT00296023", "title": "Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "nonmyeloablative allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 25, "start_date": "1999-01", "completion_date": "2008-06", "has_results": false, "last_update_posted_date": "2012-10-04", "last_synced_at": "2026-09-27T08:37:38.239Z", "location_count": 2, "location_summary": "Berkeley, California • San Francisco, California", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00296023" }, { "nct_id": "NCT07732361", "title": "A Study Using Real-world Data to Examine Outcomes in Children and Adults Who Develop a Blood Clotting Disorder Called Thrombotic Microangiopathy (TMA) After Undergoing a Hematopoietic Stem Cell Transplant (HSCT).", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Thrombotic Microangiopathy", "Hematopoietic Stem Cell Transplant" ], "interventions": [], "intervention_types": [], "sponsor": "Alexion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Weeks", "maximum_age": null, "sex": "ALL", "summary": "4 Weeks and older" }, "enrollment_count": 307, "start_date": "2025-01-22", "completion_date": "2026-03-31", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-09-27T08:37:38.239Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Akron, Ohio • Salt Lake City, Utah", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Akron", "state": "Ohio" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT07732361" }, { "nct_id": "NCT03734588", "title": "Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adeno-Associated Virus (AAV)", "Blood Coagulation Disorder", "Blood Coagulation Disorders, Inherited", "Coagulation Protein Disorders", "Factor VIII (FVIII)", "Factor VIII (FVIII) Deficiency", "Factor VIII (FVIII) Gene", "Factor VIII (FVIII) Protein", "Genetic Diseases, Inborn", "Genetic Diseases, X-Linked", "Gene Therapy", "Gene Transfer", "Hematologic Diseases", "Hemorrhagic Disorders", "Recombinant", "Vector", "Inhibitors" ], "interventions": [ { "name": "SPK-8016", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Spark Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 4, "start_date": "2019-01-30", "completion_date": "2023-01-19", "has_results": true, "last_update_posted_date": "2024-02-23", "last_synced_at": "2026-09-27T08:37:38.239Z", "location_count": 11, "location_summary": "Los Angeles, California • Peoria, Illinois • Ann Arbor, Michigan + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Madison", "state": "Mississippi" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03734588" } ] }